Department of Neurology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
Department of Neurology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
World Neurosurg. 2024 Mar;183:e470-e482. doi: 10.1016/j.wneu.2023.12.122. Epub 2023 Dec 28.
The correlation between hyperdense basilar artery sign (HDBAS) and outcome after acute basilar artery occlusion (ABAO) is debated. Our objective was to determine the usefulness of HDBAS in predicting the outcomes of patients with ABAO after endovascular treatment (EVT), intravenous thrombolysis (IVT), and best medical treatment (BMT).
The study participants were selected from the ATTENTION trial. The primary outcome of the study was a 90-day modified Rankin Scale (mRS) score, and the secondary outcome was the recanalization rate, any intracranial hemorrhage, and 90-day mortality.
The study comprised 276 participants, with cohorts for EVT (n = 188), IVT (n = 82), and BMT (n = 88). In the EVT cohort, HDBAS was not associated with 90-day mRS score (adjusted odds ratio [OR], 0.87; 95% confidence interval [CI], 0.51-1.48; P = 0.6029), the recanalization after 24 hours of onset (adjusted OR, 0.76; 95% CI, 0.30-3.61; P = 0.9422), and 90-day mortality (adjusted OR, 0.77; 95% CI, 0.41-1.46; P = 0.4238). In the IVT cohort, HDBAS was not associated with a 90-day mRS score (adjusted OR, 0.69; 95% CI, 0.31-1.56; P = 0.3742), the recanalization after 24 hours of onset (adjusted OR, 2.24; 95% CI, 0.47-10.78; P = 0.3132), and 90-day mortality (adjusted OR, 0.64; 95% CI, 0.26-1.57; P = 0.3264). Similarly, in the BMT cohort, HDBAS was not associated with 90-day mRS score (adjusted OR, 1.11; 95% CI, 0.47-2.63; P = 0.8152), the recanalization after 24 hours of onset (adjusted OR, 1.27; 95% CI, 0.40-4.02; P = 0.6874), and 90-day mortality (adjusted OR, 1.17; 95% CI, 0.46-2.96; P = 0.748).
HDBAS may not be a reliable predictor of outcomes for patients with ABAO, regardless of whether they received EVT, IVT, or BMT.
高密度基底动脉征(HDBAS)与急性基底动脉闭塞(ABAO)后结局之间的相关性存在争议。我们的目的是确定 HDBAS 在预测接受血管内治疗(EVT)、静脉溶栓(IVT)和最佳药物治疗(BMT)的 ABAO 患者结局方面的有用性。
研究参与者选自 ATTENTION 试验。研究的主要结局是 90 天改良 Rankin 量表(mRS)评分,次要结局是再通率、任何颅内出血和 90 天死亡率。
研究包括 276 名参与者,EVT 队列(n=188)、IVT 队列(n=82)和 BMT 队列(n=88)。在 EVT 队列中,HDBAS 与 90 天 mRS 评分(校正优势比[OR],0.87;95%置信区间[CI],0.51-1.48;P=0.6029)、24 小时后再通(校正 OR,0.76;95%CI,0.30-3.61;P=0.9422)和 90 天死亡率(校正 OR,0.77;95%CI,0.41-1.46;P=0.4238)无关。在 IVT 队列中,HDBAS 与 90 天 mRS 评分(校正 OR,0.69;95%CI,0.31-1.56;P=0.3742)、24 小时后再通(校正 OR,2.24;95%CI,0.47-10.78;P=0.3132)和 90 天死亡率(校正 OR,0.64;95%CI,0.26-1.57;P=0.3264)无关。同样,在 BMT 队列中,HDBAS 与 90 天 mRS 评分(校正 OR,1.11;95%CI,0.47-2.63;P=0.8152)、24 小时后再通(校正 OR,1.27;95%CI,0.40-4.02;P=0.6874)和 90 天死亡率(校正 OR,1.17;95%CI,0.46-2.96;P=0.748)无关。
无论患者接受 EVT、IVT 还是 BMT,HDBAS 可能都不是 ABAO 患者结局的可靠预测指标。